Navigation Links
AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
Date:2/17/2011

ALISO VIEJO, Calif., Feb. 17, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced the promotion of Gregory J. Flesher to the position of Senior Vice President of Corporate Development and Chief Business Officer.  In this role, Mr. Flesher will oversee corporate strategy, business development, program management, and business operations.

"Greg has shown exceptional leadership over the past several years and has played a key role in the transformation of AVANIR into a commercial-stage organization," said Keith Katkin, President and Chief Executive Officer.  "His broad pharmaceutical background in business development, sales and marketing, and research and development provides a strong foundation which will help AVANIR grow into a successful CNS company.  I look forward to Greg's continued contributions to the executive management team."

Mr. Flesher has over 16 years of experience in the pharmaceutical industry.  He was previously Vice President of Business Development for AVANIR, with responsibility for business transactions, intellectual property, and NUEDEXTA™ lifecycle planning.  Prior to joining the Company, he held various positions of increasing responsibility at InterMune Inc., Amgen Inc., and Eli Lilly and Company.

Mr. Flesher graduated from Purdue University with a degree in Biology and has completed his doctorate coursework in Biochemistry and Molecular Biology at Indiana University School of Medicine.

About AVANIR Pharmaceuticals, Inc.

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about AVANIR, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by AVANIR Pharmaceuticals, Inc.

©2011 AVANIR Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
2. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
3. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
4. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
6. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
7. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):